A5064958419- Electrolyte and hormonal disorders
- Intelligent Tutoring Systems and Adaptive Learning
- Natural Language Processing Techniques
- Inflammatory mediators and NSAID effects
- Dialysis and Renal Disease Management
- Software Engineering Research
- Renal function and acid-base balance
- Pharmaceutical studies and practices
- Cardiovascular Function and Risk Factors
- Epilepsy research and treatment
- Gastroesophageal reflux and treatments
- Drug Transport and Resistance Mechanisms
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Pharmacological Effects and Toxicity Studies
University of Florida
2024-2025
Helwan University
2024-2025
The high failure rate of central nervous system (CNS) drugs is partly associated with an insufficient understanding target site exposure. Blood–brain barrier (BBB) permeability evaluation tools are needed to explore drugs’ ability access the CNS. An outstanding aspect physiologically based pharmacokinetic (PBPK) models integration knowledge on drug-specific and system-specific characteristics, allowing identification relevant factors involved in distribution. We aimed qualify a PBPK platform...
Objectives: Spironolactone (SP) is a potassium-sparing diuretic medication that has been in the market for more than 60 years. SP complex pharmacokinetics (PK) which includes poor solubility, metabolism, and multiple active metabolites. Limited research comprehensively addressed clinical PK, efficacy safety, resulting persisting knowledge gaps. Additionally, used off-label pediatrics since its approval. Several challenges are thus faced to inform use derived from this lack of substantial...
Background/Objectives: Spironolactone (SP) has been used off-label in pediatrics since its approval, but use is challenged by limited pharmacokinetic (PK) data adults and especially children. Methods: Physiologically based (PBPK) models for SP active metabolites, canrenone (CAN) 7α thio-methyl spironolactone (TMS), were developed. These aim to enhance understanding of SP’s PK provide a basis predicting optimizing dosing infants neonates. Given complex metabolism, we assumed complete...
Background/Objectives: Omeprazole is widely used for managing gastrointestinal disorders like GERD, ulcers, and H. pylori infections. However, its use in pediatrics presents challenges due to drug interactions (DDIs), metabolic variability, safety concerns. Omeprazole’s pharmacokinetics (PK), primarily influenced by CYP2C19 metabolism, affected ontogenetic changes enzyme expression, complicating dosing children. Methods: This study aimed develop validate a physiologically based...
Abstract This study employed physiologically‐based pharmacokinetic–pharmacodynamics (PBPK/PD) modeling to predict the effect of obesity and gastric bypass surgery on pharmacokinetics intragastric pH following omeprazole treatment. The simulated plasma concentrations closely matched observed data from non‐obese, morbidly obese, post‐gastric populations. Obesity significantly reduces CYP3A4 CYP2C19 activities, as reflected by metabolic ratio [omeprazole sulphone]/[omeprazole]...
Chronic kidney disease (CKD) often results in renal anemia, impacting the well-being of patients and causing various negative consequences. Erythropoiesis-stimulating agents (ESAs) offer promising solutions for managing anemia CKD. This study aimed to evaluate compare effectiveness, safety profile, cost-effectiveness short-acting (Eprex